DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intuniv (Guanfacine Hydrochloride) - Published Studies

 
 



Intuniv Related Published Studies

Well-designed clinical trials related to Intuniv (Guanfacine)

Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form. [2014]

Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. [2013]

Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. [2013]

Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]

Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010]

Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. [2010]

Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. [2009.02]

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. [2008.01]

A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. [2008]

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. [2007.09]

The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. [2007.05.15]

A phase i, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. [2007.04]

Well-designed clinical trials possibly related to Intuniv (Guanfacine)

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. [2011]

Pharmacotherapeutics of Tourette syndrome and stereotypies in autism. [2010.12]

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. [2010.11]

Other research related to Intuniv (Guanfacine)

Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. [2014]

A HPLC-MS method to detect and quantify guanfacine in urine. [2011.11.24]

Dried blood spots as a sampling technique for the quantitative determination of guanfacine in clinical studies. [2011.11]

Attention deficits following ADEM ameliorated by guanfacine. [2011.06]

Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. [2011.04]

Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response. [2011]

Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). [2010.10]

Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. [2010.05]

Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. [2010.03]

Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. [2010.02]

Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension. [2010.02]

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. [2009.10]

Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. [2009.08.15]

Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. [2009.06]

Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. [2008.12]

The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. [2008.09]

Guanfacine in children with autism and/or intellectual disabilities. [2008.08]

Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. [2007.09]

Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. [2007.01]

Other possibly related research studies

Changes in Emotions Related to Medication Used to Treat ADHD. Part I: A Literature Review. [2010.09.28]

Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. [2010.02]

Cognitive enhancement as a pharmacotherapy target for stimulant addiction. [2010.01]

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. [2010]

Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. [2009.12]

Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. [2009.12]

Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. [2009]

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. [2009]

Carbamazepine-induced hyperammonemia. [2009.08.15]

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. [2009.09]

Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. [2009.10]

Attention-deficit-hyperactivity disorder: an update. [2009.06]

Neuroleptic malignant syndrome secondary to quetiapine. [2009.04]

Dopamine vs noradrenaline: inverted-U effects and ADHD theories. [2009.02]

Changes and challenges: managing ADHD in a fast-paced world. [2007.11]

Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. [2008.02]

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. [2007.08]

Centrally acting antihypertensive agents: an update. [2007.05]

Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. [2007.03]

Differential noradrenergic influence on seizure expression in genetically Fast and Slow kindling rat strains during massed trial stimulation of the amygdala. [2007.02]

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. [2010.12]

Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy. [2011]

Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. [2011.07.15]

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. [2011.07.01]

Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. [2011.06.15]

Cognitive enhancers for the treatment of ADHD. [2011.08]

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. [2011.04.13]

Catecholamine influences on dorsolateral prefrontal cortical networks. [2011.06.15]

Comparison of SHR, WKY and Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists. [2011.03]

Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. [2011.02]

The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. [2010.10]

Changes in emotions related to medication used to treat ADHD. Part I: literature review. [2011.02]

The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. [2010.09]

Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders. [2010.10]

Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. [2012]

Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. [2012]

Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. [2011]

Pharmacotherapeutics of Tourette syndrome and stereotypies in autism. [2010]

Alpha2-adrenergic agonists for the management of opioid withdrawal. [2014]

Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017